Although treatment with erlotinib inhibited EGFR and pERK phosphorylation of the RAF-RAS-MEK pathway in the A431 cell line and mouse NCI-H292 tumor xenografts, there was no effect on pAKT and pRAS40, downstream markers of AKT inhibition. The gene discussed is AKT1; the disease is neoplasm.